Nicole Forestier

3.9k total citations · 1 hit paper
38 papers, 3.0k citations indexed

About

Nicole Forestier is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Nicole Forestier has authored 38 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hepatology, 19 papers in Epidemiology and 7 papers in Rheumatology. Recurrent topics in Nicole Forestier's work include Hepatitis C virus research (31 papers), Liver Disease Diagnosis and Treatment (16 papers) and Hepatitis B Virus Studies (13 papers). Nicole Forestier is often cited by papers focused on Hepatitis C virus research (31 papers), Liver Disease Diagnosis and Treatment (16 papers) and Hepatitis B Virus Studies (13 papers). Nicole Forestier collaborates with scholars based in Germany, United States and France. Nicole Forestier's co-authors include Stefan Zeuzem, Tara L. Kieffer, Christoph Sarrazin, Lindsay McNair, Hendrik W. Reesink, Ann D. Kwong, John Alam, Robert S. Kauffman, Martin Welker and Susan Purdy and has published in prestigious journals such as New England Journal of Medicine, Circulation and Gastroenterology.

In The Last Decade

Nicole Forestier

37 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

2009 771 citations Christophe Hézode, Nicole Forestier et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicole Forestier Germany	19	2.3k	1.9k	704	441	292	38	3.0k
Kaname Yoshizawa Japan	33	3.0k 1.3×	3.2k 1.7×	214 0.3×	391 0.9×	117 0.4×	124	4.7k
Hans Dieter Nischalke Germany	32	1.4k 0.6×	1.3k 0.7×	222 0.3×	322 0.7×	79 0.3×	91	2.8k
Tung‐Hung Su Taiwan	34	3.2k 1.4×	3.2k 1.7×	291 0.4×	315 0.7×	122 0.4×	188	4.0k
Christoph Welsch Germany	23	1.5k 0.7×	1.2k 0.7×	431 0.6×	385 0.9×	32 0.1×	89	2.1k
Carmela Cursaro Italy	25	1.6k 0.7×	1.4k 0.8×	179 0.3×	184 0.4×	105 0.4×	95	2.1k
E. Del Ninno Italy	27	3.8k 1.6×	3.6k 1.9×	159 0.2×	279 0.6×	113 0.4×	74	4.6k
Kiyoaki Ito Japan	27	1.5k 0.6×	1.9k 1.0×	204 0.3×	439 1.0×	306 1.0×	170	2.8k
Shingo Nakamoto Japan	23	1.0k 0.5×	844 0.5×	222 0.3×	245 0.6×	151 0.5×	107	1.6k
Anita Kohli United States	24	1.2k 0.5×	1.5k 0.8×	304 0.4×	249 0.6×	48 0.2×	77	2.2k
Tatsuya Ide Japan	20	2.2k 0.9×	2.2k 1.2×	174 0.2×	301 0.7×	34 0.1×	120	2.9k

Countries citing papers authored by Nicole Forestier

Since Specialization

Citations

This map shows the geographic impact of Nicole Forestier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicole Forestier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicole Forestier more than expected).

Fields of papers citing papers by Nicole Forestier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicole Forestier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicole Forestier. The network helps show where Nicole Forestier may publish in the future.

Co-authorship network of co-authors of Nicole Forestier

This figure shows the co-authorship network connecting the top 25 collaborators of Nicole Forestier. A scholar is included among the top collaborators of Nicole Forestier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicole Forestier. Nicole Forestier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grimsmann, Julia M., Christina Reinauer, Andreas Melmer, et al.. (2020). Continuous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Data from the German/Austrian Prospective Diabetes Follow-Up Registry. Diabetes Technology & Therapeutics. 22(8). 602–612. 33 indexed citations

Vermehren, Johannes, Amina Carlebach, Thomas A. Lutz, et al.. (2012). Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers. BMC Gastroenterology. 12(1). 27–27. 19 indexed citations

Forestier, Nicole & Stefan Zeuzem. (2012). Telaprevir for the treatment of hepatitis C. Expert Opinion on Pharmacotherapy. 13(4). 593–606. 18 indexed citations

Vermehren, Johannes, S. Süsser, Christian M. Lange, et al.. (2011). Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa‐2b. Journal of Viral Hepatitis. 19(2). 120–127. 39 indexed citations

Süsser, S., Johannes Vermehren, Nicole Forestier, et al.. (2011). Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. Journal of Clinical Virology. 52(4). 321–327. 87 indexed citations

Waidmann, Oliver, Verena Bihrer, Bernd Kronenberger, et al.. (2011). Pretreatment serum microRNA-122 is not predictive for treatment response in chronic hepatitis C virus infection. Digestive and Liver Disease. 44(5). 438–441. 14 indexed citations

Forestier, Nicole, Dominique Larrey, Patrick Marcellin, et al.. (2011). Antiviral Activity of Danoprevir (ITMN-191/RG7227) in Combination With Pegylated Interferon α-2a and Ribavirin in Patients With Hepatitis C. The Journal of Infectious Diseases. 204(4). 601–608. 14 indexed citations

Forestier, Nicole, Dominique Larrey, Dominique Guyader, et al.. (2010). Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study. Journal of Hepatology. 54(6). 1130–1136. 48 indexed citations

Moucari, Rami, Nicole Forestier, Dominique Larrey, et al.. (2010). Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut. 59(12). 1694–1698. 51 indexed citations

10.

Hézode, Christophe, Nicole Forestier, Geoffrey Dusheiko, et al.. (2009). Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. New England Journal of Medicine. 360(18). 1839–1850. 771 indexed citations breakdown →

11.

Hézode, Christophe, Péter Ferenci, Geoffrey Dusheiko, et al.. (2008). 160 Prove2 Study: Treatment of Chronic Hepatitis C with Telaprevir (TVR)in Combination with Peginterferon-Alfa-2a with or Without Ribavirin, Interim Analysis Results. Gastroenterology. 134(4). A–755. 4 indexed citations

12.

Potthoff, Andrej, Heiner Wedemeyer, Wulf O. Boecher, et al.. (2008). The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection. Journal of Hepatology. 49(5). 688–694. 56 indexed citations

13.

Welsch, Christoph, Nicole Forestier, Bernd Kronenberger, et al.. (2008). Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease. European Journal of Gastroenterology & Hepatology. 20(9). 865–873. 18 indexed citations

14.

Gelderblom, Huub C., Stefan Zeuzem, Christine J. Weegink, et al.. (2008). Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3•4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a. Scandinavian Journal of Gastroenterology. 43(9). 1122–1127. 10 indexed citations

15.

Kronenberger, Bernd, Christoph Welsch, Nicole Forestier, & Stefan Zeuzem. (2008). Novel Hepatitis C Drugs in Current Trials. Clinics in Liver Disease. 12(3). 529–555. 17 indexed citations

16.

Kieffer, Tara L., Christoph Sarrazin, Janice S. Miller, et al.. (2007). Telaprevir and pegylated interferon–alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology. 46(3). 631–639. 297 indexed citations

17.

Sarrazin, Christoph, Roman Rouzier, Frank Wagner, et al.. (2007). SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders. Gastroenterology. 132(4). 1270–1278. 227 indexed citations

18.

Gelderblom, Huub C., Stefan Zeuzem, Nicole Forestier, et al.. (2007). [592] NEOPTERIN AND ALT AS MARKERS OF INFLAMMATION IN CHRONIC HEPATITIS C PATIENTS DURING ADMINISTRATION OF THE HCV NS3-4A PROTEASE INHIBITOR TELAPREVIR (VX-950) IN COMBINATION WITH PEGINTERFERON ALFA 2a. Journal of Hepatology. 46. S224–S225. 2 indexed citations

19.

Forestier, Nicole, Hendrik W. Reesink, Christine J. Weegink, et al.. (2007). Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 46(3). 640–648. 189 indexed citations

20.

Wilkens, Heinrike, Angelika Guth, J. König, et al.. (2001). Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension. Circulation. 104(11). 1218–1222. 316 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact